baltimore conference logo
  • MJHLS Brand Logo

© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Case-Based Peer Perspectives

Targeted Oncology presents Case-Based Peer Perspectives. In each video, expert physicians provide insight on managing oncology-based patient cases that highlight the use of novel agents in clinical practice.

A 68-Year-Old Woman With Stage IV Ovarian Cancer

A 68-Year-Old Woman With Stage IV Ovarian Cancer
A 68-Year-Old Woman With Stage IV Ovarian Cancer
Molecular Testing in Newly Diagnosed Patients
Molecular Testing in Newly Diagnosed Patients
Frontline Therapy Options for Stage IV Ovarian Cancer
Frontline Therapy Options for Stage IV Ovarian Cancer
GOG-0218 and ICON7 Trial Regimens as Maintenance Therapy
GOG-0218 and ICON7 Trial Regimens as Maintenance Therapy
Maintenance Therapy: NCCN Guidelines, PAOLA-1 Trial
Maintenance Therapy: NCCN Guidelines, PAOLA-1 Trial
Emerging Frontline and I/O PARP Combination Therapies
Emerging Frontline and I/O PARP Combination Therapies
The Direction of Ovarian Cancer Management
The Direction of Ovarian Cancer Management

A 69-Year-Old Woman With Follicular Lymphoma

Diagnosis of a 69-Year-Old Woman With Follicular Lymphoma
Diagnosis of a 69-Year-Old Woman With Follicular Lymphoma
Follicular Lymphoma: Prognostic Scoring and Treatment Decisions
Follicular Lymphoma: Prognostic Scoring and Treatment Decisions
Maintenance Therapy for Follicular Lymphoma
Maintenance Therapy for Follicular Lymphoma
Follicular Lymphoma: Treating Early Progression
Follicular Lymphoma: Treating Early Progression
PI3K Inhibition for R/R Follicular Lymphoma
PI3K Inhibition for R/R Follicular Lymphoma
Treating R/R Follicular Lymphoma With PI3K Inhibitors
Treating R/R Follicular Lymphoma With PI3K Inhibitors
Novel Therapies for Patients With Follicular Lymphoma
Novel Therapies for Patients With Follicular Lymphoma

A 49-Year-Old Man With Steroid-Refractory Chronic Graft Versus Host Disease

Case Overview: 49-Year-Old Man With Chronic GvHD
Case Overview: 49-Year-Old Man With Chronic GvHD
Definition of GvHD
Definition of GvHD
Treatment Options for Chronic GvHD
Treatment Options for Chronic GvHD
Steroid-Refractory GvHD: Treatment With JAK Inhibitors
Steroid-Refractory GvHD: Treatment With JAK Inhibitors
Emerging Agents for the Treatment of Chronic GvHD
Emerging Agents for the Treatment of Chronic GvHD
Future Directions and Unmet Needs in Chronic GvHD
Future Directions and Unmet Needs in Chronic GvHD

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

A 68-Year-Old Man With Metastatic EGFR+ NSCLC
A 68-Year-Old Man With Metastatic EGFR+ NSCLC
Improved Outcomes for Patients With EGFR+ NSCLC
Improved Outcomes for Patients With EGFR+ NSCLC
Molecular Testing for Newly Diagnosed NSCLC
Molecular Testing for Newly Diagnosed NSCLC
Treatment Options for EGFR+ NSCLC
Treatment Options for EGFR+ NSCLC
Practical Implications of the RELAY Trial in EGFR+ NSCLC
Practical Implications of the RELAY Trial in EGFR+ NSCLC
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC
Repeat Testing at Progression of EGFR+ NSCLC
Repeat Testing at Progression of EGFR+ NSCLC
Changing Landscape of EGFR+ mNSCLC
Changing Landscape of EGFR+ mNSCLC

A 69-Year-Old Man With Advanced Castrate-Resistant Prostate Cancer

Case Overview: 69-Year-Old Man With Advanced CRPC
Case Overview: 69-Year-Old Man With Advanced CRPC
Standard of Care for mCRPC
Standard of Care for mCRPC
Therapeutic Options for mCRPC
Therapeutic Options for mCRPC
Approaching Therapy for mCRPC
Approaching Therapy for mCRPC
Management of mCRPC: Radium-223
Management of mCRPC: Radium-223
Radium 223: Counseling Patients With mCRPC
Radium 223: Counseling Patients With mCRPC
Combination of Radium-223 With Other Novel Agents in mCRPC
Combination of Radium-223 With Other Novel Agents in mCRPC
Importance of Bone Health Agents in mCRPC Management
Importance of Bone Health Agents in mCRPC Management
Role of Multidisciplinary Management in mCRPC
Role of Multidisciplinary Management in mCRPC

A 68-Year-Old Man With Mantle Cell Lymphoma

Case Assessment: 68-Year-Old Patient With MCL
Case Assessment: 68-Year-Old Patient With MCL
Diagnosing MCL and Making Informed Treatment Decisions
Diagnosing MCL and Making Informed Treatment Decisions
Initiating Therapy for Mantle Cell Lymphoma
Initiating Therapy for Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma Treatment Landscape
Relapsed Mantle Cell Lymphoma Treatment Landscape
Administration of BTK Inhibitors for Mantle Cell Lymphoma
Administration of BTK Inhibitors for Mantle Cell Lymphoma
BTK Inhibitor Toxicities in Mantle Cell Lymphoma
BTK Inhibitor Toxicities in Mantle Cell Lymphoma
BTK Inhibitors in MCL: Long-Term Safety & Efficacy Data
BTK Inhibitors in MCL: Long-Term Safety & Efficacy Data
Next Steps in Relapsed/Refractory Mantle Cell Lymphoma
Next Steps in Relapsed/Refractory Mantle Cell Lymphoma